Financials data is unavailable for this security.
View more
Year on year Nanjing Vazyme Biotech Co Ltd 's revenues fell -63.97% from 3.57bn to 1.29bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 594.25m to a loss of 70.96m.
Gross margin | 69.94% |
---|---|
Net profit margin | 1.79% |
Operating margin | 0.26% |
Return on assets | 0.46% |
---|---|
Return on equity | 0.66% |
Return on investment | 0.58% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Nanjing Vazyme Biotech Co Ltd fell by 496.40m. Cash Flow from Financing totalled 249.80m or 19.42% of revenues. In addition the company generated 152.99m in cash from operations while cash used for investing totalled 900.65m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 10.06 |
---|---|
Tangible book value per share | 9.49 |
More ▼
Balance sheet in CNYView more
Current ratio | 4.57 |
---|---|
Quick ratio | 4.09 |
Total debt/total equity | 0.1768 |
---|---|
Total debt/total capital | 0.1502 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -92.00% and -112.12%, respectively.
Div yield(5 year avg) | 0.59% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | 150.97% |
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 126.20 |
More ▼